Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2022

View Archived Issues

New PET ligand allows in vivo pharmacological evaluation of agents targeting mutant HTT expression

New in vitro model represents the 3D architecture, composition and mechanics of connective tissues

DPEP1 antagonist LSALT shows promise in preclinical models of acute kidney injury

Scientists identify role of PDGF-D-PDGFR-beta signaling pathway in survival of human NK cells

Discovery of novel monoclonal antibodies against emerging SARS-CoV-2 variants of concern

Non-muscle-targeted AAV8/DC190-ASM gene therapy for treating limb girdle muscular dystrophy 2B

IFM Due patents hSTING antagonists for cancer

Nanjing Zhengxiang Pharmaceuticals divulges DHODH inhibitors

Korean researchers synthesize PDE5A and HDAC6 dual inhibitors for Alzheimer's

Caregen identifies new antivirals for SARS-CoV-2

Eisai divulges new OX2 receptor agonists for narcolepsy

MDL-001 significantly reduces SARS-CoV-2 viral load in lungs in preclinical study

Immunome's antibody cocktail effective against live versions of SARS-CoV-2 Omicron variant in vitro

Xanadu signs agreements with Yale to support development of intranasal SARS-CoV-2 vaccine booster

SENS-401 shows good local bioavailability in sensorineural hearing loss model

For pain signaling, endocytosis is not the end

New drug combinations with synergistic inhibitory activity against SARS-CoV-2

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...